Barnett & Company’s Bristol-Myers Squibb BMY Stock Holding History

Barnett & Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,110	Closed	-$1.3M	–	89
2025 Q4	$1.3M	Buy	24,110 +3,900	+19%	+$188K	1.05%	30
2025 Q3	$911K	Buy	20,210 +3,400	+20%	+$159K	0.7%	42
2025 Q2	$778K	Buy	+16,810	New	+$825K	0.61%	46
2022 Q1	–	Sell	-1,715	Closed	-$107K	–	119
2021 Q4	$107K	Sell	1,715 -40	-2%	-$2.35K	0.07%	113
2021 Q3	$104K	Sell	1,755 -104	-6%	-$6.85K	0.08%	103
2021 Q2	$124K	Sell	1,859 -46	-2%	-$3K	0.08%	109
2021 Q1	$120K	Sell	1,905 -300	-14%	-$18.7K	0.06%	125
2020 Q4	$136K	Hold	2,205	–	–	0.09%	111
2020 Q3	$133K	Hold	2,205	–	–	0.09%	110
2020 Q2	$130K	Sell	2,205 -300	-12%	-$17.9K	0.11%	102
2020 Q1	$140K	Hold	2,505	–	–	0.13%	93
2019 Q4	$161K	Buy	+2,505	New	+$143K	0.1%	110
2016 Q3	–	Sell	-459	Closed	-$34K	–	393
2016 Q2	$34K	Hold	459	–	–	0.02%	221
2016 Q1	$29K	Buy	+459	New	+$28.9K	0.02%	245

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barnett & Company's BMY Position: Q1 2026 in Review

Barnett & Company sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 24,110 shares — an estimated $1.3M sold.

Barnett & Company first reported a position in BMY in Q1 2016 and held it in 14 quarters. The position peaked at $1.3M in Q4 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Barnett & Company reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Barnett & Company sold 24,110 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.3M.
Barnett & Company first reported a position in Bristol-Myers Squibb in Q1 2016 and held it in 14 quarters.
Barnett & Company's Bristol-Myers Squibb position peaked at $1.3M in Q4 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Barnett & Company's 13F filing for Q1 2026, filed 30 Apr 2026.